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Aims Congo red staining of an endomyocardial biopsy is the diagnostic gold-standard in suspected cardiac amyloidosis
(CA), but the procedure is associated with the risk, albeit small, of serious complications, and delay in diagnosis
due to the requirement for technical expertise. In contrast, abdominal fat pad fine needle aspiration (FPFNA) is a
simple, safe and well-established procedure in systemic amyloidosis, but its diagnostic sensitivity in patients with
suspected CA remains unclear.
...................................................................................................................................................................................................
Methods
and results
We assessed the diagnostic sensitivity of FPFNA in 600 consecutive patients diagnosed with CA [216 AL amyloid-
osis, 113 hereditary transthyretin (ATTRm), and 271 wild-type transthyretin (ATTRwt) amyloidosis] at our Centre.
Amyloid was detected on Congo red staining of FPFNAs in 181/216 (84%) patients with cardiac AL amyloidosis,
including 100, 97, and 78% of those with a large, moderate, and small whole-body amyloid burden, respectively, as
assessed by serum amyloid P (SAP) component scintigraphy (P < 0.001); the deposits were successfully typed as
AL by immunohistochemistry in 102/216 (47%) cases. Amyloid was detected in FPFNAs of 51/113 (45%) patients
with ATTRm CA, and only 42/271 (15%) cases with ATTRwt CA.
...................................................................................................................................................................................................
Conclusions FPFNA has reasonable diagnostic sensitivity in cardiac AL amyloidosis, particularly in patients with a large whole-
body amyloid burden. Although the diagnostic sensitivity of FPFNA is substantially lower in transthyretin CA,
particularly ATTRwt, it may nevertheless sometimes obviate the need for endomyocardial biopsy.
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Introduction
Systemic amyloidosis is usually diagnosed via Congo red staining of a
biopsy from a clinically affected organ but, when suspected, may be
diagnosed through a so-called ‘screening biopsy’ of rectum,1,2 salivary
gland,3 or fat,4 avoiding the risks, costs and delay associated with
biopsies of organs such as the heart and liver.5
Cardiac amyloidosis (CA) is a common manifestation and the
major determinant of prognosis in systemic immunoglobulin light
chain (AL) amyloidosis.6,7 CA is also the commonest presenting
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feature of transthyretin (ATTR) amyloidosis,8,9 and is the domin-
ant phenotypic manifestation in both wild-type ATTR amyloidosis
(ATTRwt), which is increasingly diagnosed in the elderly male
population,10 and the most common form of mutant cardiac
ATTR amyloidosis (ATTRm), that associated with the V122I
variant.8
Endomyocardial biopsy, the diagnostic gold standard for detection
of CA, is associated with a small risk of serious complications, high
cost, and a requirement for specialist technical expertise and hospital
equipment which are not widely available and may introduce delay.5
An alternative diagnostic test with high sensitivity which can be per-
formed at the bedside, is thus particularly desirable in patients with
suspected CA. Congo red staining of an abdominal fat pad fine needle
aspiration (FPFNA) is a simple, cheap, low risk procedure that is cur-
rently the most widely used screening biopsy technique in patients
with suspected systemic amyloidosis.11 Unlike other screening biopsy
techniques such as rectal, salivary gland or formal fat biopsy, it does
not require a surgical incision, blunt dissection, surgical re-
approximation, or suture. Although the specificity of FPFNA for
amyloid is unequivocally high,4 its diagnostic sensitivity has been re-
ported to be as low as 14% in certain series and >90% in others.12,13
The diagnostic performance of FPFNA in certain types of ATTR
amyloidosis has previously been reported,12 but there has never
been a systematic study comparing its diagnostic sensitivity in a large
cohort of patients with different types of CA, including subtypes of
ATTRm, and the basis for the reported discrepancy in sensitivity is
not known.
We sought to determine the diagnostic sensitivity of FPFNA in
identifying and typing amyloid deposits in patients with the three
main types of CA, namely cardiac AL, cardiac ATTRm, and cardiac
ATTRwt amyloidosis. Further, we studied the relationship between
the diagnostic sensitivity of FPFNA and total body amyloid burden
hypothesizing that the presence and degree of amyloid infiltration in
fat may correlate with the extent of amyloid throughout the body in
general.
Methods
Patients
Patients with suspected CA attending the UK National Amyloidosis
Centre between 2010 and 2015 underwent a comprehensive protocol of
evaluation comprising ECG, echocardiogram, cardiac magnetic resonance
(CMR) imaging, biochemical tests including serum and urine immunofixa-
tion electrophoresis and serum free light chain assay, 123I–serum amyloid
P component (SAP) scintigraphy,14 99mTc-labelled 3,3-diphosphono-1,2-
propanodicarboxylic acid (DPD) scintigraphy,15 TTR gene sequencing,16
and where necessary, sequencing of other hereditary amyloidosis genes.
Six hundred consecutive patients with an unequivocal diagnosis and
type of CA were included in the analysis. The diagnosis of presence and
type of cardiac amyloid was established on the basis of a characteristic
echocardiogram and/or CMR for amyloid, in conjunction with histological
proof of presence and type of amyloid in 380 patients (including all those
with cardiac AL amyloidosis) and on the basis of published non-biopsy
diagnostic criteria in 220 patients with ATTR amyloidosis.17
All patients were managed in accordance with the Declaration of
Helsinki and provided informed consent for anonymous publication of
scientific data.
Fat pad fine needle aspiration
By definition, all patients included in the study underwent FPFNA, which
was performed as previously described.11 Median (range) weight of aspi-
rated material was 0.050 g (0.004–0.131). Smears from each FPFNA were
prepared on five glass slides for Congo red staining. The remainder of the
aspirated fat tissue in each case was briefly fixed in formalin, double
embedded in agar, and a paraffin block was produced for further Congo
red staining and routine immunohistochemistry (IHC). IHC was per-
formed using a panel of monospecific antibodies against the most com-
mon amyloidogenic proteins, including kappa and lambda light chains, and
transthyretin, as previously described.18 Interpretation of all stained slides
was carried out independently by two experienced examiners.
123I–serum amyloid P component
scintigraphy
Whole body anterior and posterior scintigraphic imaging was undertaken
6 or 24h after administration of 123I-labelled SAP, as previously
described.19 Whole body amyloid load burden was categorized into
small, moderate, or large in each patient, as previously described.20
Labelled SAP studies were interpreted by a panel of physicians with ex-
perience of over 10 000 SAP scans who were blinded to the FNFPA
results.
Statistical analysis
Summary statistics were expressed as mean (SD) or median (interquar-
tile range) for numerical variables and frequencies (percentages) for cat-
egorical variables. Independence of the two categorical variables defining
a contingency table was tested using Fisher’s exact test or Pearson’s chi-
square test (according to Cochran’s rule) using IBM SPSS Statistics 23
software. P-values < 0.05 were considered significant.
Results
Among 600 patients with an unequivocal diagnosis of CA, 216 had
systemic AL amyloidosis (age 65 ± 10 years), 113 had ATTRm amyl-
oidosis (age 68 ± 8 years), and 271 had ATTRwt amyloidosis (age 71
± 6 years). Details of the diagnostic pathway are provided in a
Supplementary material online, Figure S1. Cardiac AL amyloidosis
was lambda light chain isotype in 188/216 (86%) cases. Among pa-
tients with ATTRm, TTR variants were distributed as follows:
Val122Ile (n = 69), Thr60Ala (n = 21), Val30Met (n = 7), Ser77Tyr
(n = 5), Glu89Gln (n = 3), Phe44Leu (n = 2), Ile68Leu (n = 2),
Ile107Phe (n = 2), Cys10Gly (n = 1), Glu54Leu (n = 1). Of note, the
most prevalent TTR variant in our population, Val122Ile, was typically
associated with an exclusive cardiac phenotype, similar to ATTRwt,9
whereas the next most prevalent, Thr60Ala, was associated with a
variably mixed cardiomyopathy and neuropathy phenotype.21
Among 216 patients with systemic AL amyloidosis, 181 (84%) had
amyloid detected on Congo red staining of their FPFNA (Table 1).
The amyloid was definitively typed as AL by IHC of the FPFNA in
102/181 (56%) patients with amyloid present and in 102/216 (47%)
of total AL patients. Interestingly, amyloid was present in the FPFNA
of 28/28 (100%) AL amyloidosis patients with a large whole body
amyloid burden by SAP scintigraphy, 33/34 (97%) AL amyloidosis pa-
tients with a moderate whole body amyloid burden, and 120/154
(78%) of those with systemic AL amyloidosis and a small whole body
amyloid burden (P < 0.001; large/moderate vs. small load, Fisher’s
exact test).
1906 C.C. Quarta et al.
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..Among 113 patients with ATTRm CA, 51 (45%) had amyloid de-
tected on Congo red staining of their FPFNA (Table 1). The amyloid
was definitively typed as TTR by IHC of the FPFNA in 37/51 (73%)
patients with amyloid present and in 37/113 (33%) total ATTRm pa-
tients. More specifically, amyloid was identified in the fat samples of
23/69 (33%) patients with Val122Ile-associated ATTRm amyloidosis
compared with 14/21 (67%) patients with Thr60Ala-associated
ATTRm amyloidosis.
Among 271 patients with ATTRwt CA, amyloid was identified in
the FPFNA of only 42 (15%) cases (Table 1), 27 (65%) of whom had
diagnostic IHC for TTR (10% of total with ATTRwt).
Discussion and conclusions
Our study, which comprises the largest cohort to date of consecutive
patients with CA to undergo FPFNA as a diagnostic tool, supports its
use in systemic AL amyloidosis but highlights its limitations for diag-
nosis of ATTR amyloidosis, particularly ATTRwt amyloidosis.
Amyloid was identified in the FPFNA specimens of only 15% of pa-
tients with ATTRwt and the fibril protein was definitively typed as
TTR by IHC in only 10% of cases. Similarly, amyloid was only de-
tected in one third of FPFNAs from patients with Val122Ile-
associated CA, the most common type of ATTRm CA worldwide,
who typically present with a cardiomyopathic phenotype that is indis-
tinguishable from ATTRwt. It is noteworthy however, that the finding
of grade 2 or 3 cardiac uptake on bone scintigraphy in a patient with a
suggestive echocardiogram or CMR for CA who does not have evi-
dence of a monoclonal protein by serum or urine immunofixation
electrophoresis or by serum free light chain assay, is sufficient to diag-
nose cardiac ATTR amyloidosis without need for histological identifi-
cation of amyloid (i.e. in the context of a negative FPFNA or without
an FPFNA); further differentiation between ATTRwt and ATTRm
CA can then be established by genetic testing.17 When cardiac AL
amyloidosis is suspected however, typically in the context of a mono-
clonal protein or grade 0 or 1 cardiac uptake on bone scintigraphy,
FPFNA remains clinically valuable, since it is known to have high diag-
nostic specificity and may obviate the need for invasive EMB.
Furthermore, in this cohort of patients, all of whom had CA, a
negative result (i.e. absence of amyloid on FPFNA) in the absence of a
TTR mutation on gene sequencing, had a positive predictive value for
wild-type ATTR amyloidosis of 87% (CI 82–91%).
In a general cardiological setting, imaging modalities with high diag-
nostic specificity for cardiac amyloid, such as bone scintigraphy and/
or CMR imaging are likely to have higher sensitivity for CA, particu-
larly ATTR CA, than FPFNA and should probably therefore, be em-
ployed earlier in the course of the investigative pathway. Although
there are no formal guidelines on the diagnostic pathway for patients
with suspected CA, existing guidelines on diagnosis and management
of hypertrophic cardiomyopathy suggest consideration of EMB in sus-
pected infiltrative cardiomyopathy. Due to the simplicity and rapidity
of the procedure, we would suggest that FPFNA should be per-
formed before recourse to EMB in such cases.22
The strong association between total body amyloid burden as esti-
mated by SAP scintigraphy and the likelihood of identifying amyloid
deposits on FPFNA is noteworthy, although perhaps not surprising.
Quite simply, the more extensive the amyloid, the higher the chance
of finding deposits within a FPFNA sample. Since all FPFNAs were
performed and analysed at a single centre which has widely recog-
nized experience in the histological assessment of amyloid deposits
from a variety of different tissues, the differences in diagnostic yield
identified here between phenotypically different patients, are likely to
reflect ‘true’ amyloid deposition rather than differing experience or
practice, or varying diagnostic technique. SAP scintigraphy is most
sensitive for identifying amyloid in large solid organs such as liver,
spleen, kidney, and bone, which are commonly involved in AL amyl-
oidosis, but is unable to identify amyloid deposits in non-solid or very
diffuse organs such as the heart, nerves or gastrointestinal tract which
are those involved in ATTR amyloidosis. Nonetheless, an extensively
amyloidotic liver and spleen may contain8 kg of amyloid compared
with an extensively amyloidotic heart which contains 500mg such
that the estimate of total amyloid burden by SAP scintigraphy remains
valid even among those with extensive CA. The higher diagnostic
sensitivity of FPFNA in Thr60Ala-associated ATTRm amyloidosis,
which typically involves the peripheral and autonomic nerves as well
as the heart, compared with Val122Ile-associated ATTRm and
ATTRwt amyloidosis, which typically cause a late onset restrictive
.................................................................................................
Table 1 Diagnostic sensitivity of fat pad fine needle
aspiration in different cardiac amyloidoses
Amyloid type n Number
positive
by Congo
red staining
Diagnostic
sensitivity
(CI)
Systemic AL amyloidosis 216 181 84% (78–88%)
ATTRm 113 51 45% (36–54%)
Val122Ile 69 23 33%
Thr60Ala 21 14 67%
ATTRwt 271 42 15% (11–20%)
Systemic AL amyloidosis vs. ATTR amyloidosis, P < 0.001 (Chi square test). The
combination of absence of amyloid on FPFNA and absence of a TTR mutation on
gene sequencing, had a positive predictive value for ATTRwt in this series of 87%
(CI 82–91%) and a negative predictive value of 81% (CI 75–86%).
.................................................................................................
Table 2 Relationship between diagnostic sensitivity of
fat pad fine needle aspiration and total body amyloid
burden
Amyloid type Total body
amyloid load
by SAP
scintigraphy
Amyloid
detected
on FNFPA
Diagnostic
sensitivity
Systemic AL
amyloidosis
Large 28/28 100%
Moderate 33/34 97%
Small 120/154 78%
ATTRm Smalla,b 51/113 45%
ATTRwt Smalla 42/271 15%
Amyloid deposits in the gastrointestinal tracta and nervesb are not visualized by
SAP scintigraphy. Large/moderate load vs. Small load in AL, P<0.001 (Fisher’s
exact test), Large/moderate load vs. Small load (all patients), P<0.001 (Chi
Square test).
Abdominal fat aspiration in amyloidosis 1907
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cardiomyopathy in the absence of significant extra-cardiac involve-
ment, is consistent with greater systemic involvement in Thr60Ala
patients. It is not known whether the diagnostic yield of screening
biopsies from other sites has an association with whole body amyloid
load. The possibility that proteomic analysis of FPFNA specimens
might result in higher diagnostic sensitivity was not addressed here,
and also merits further evaluation.23
In conclusion, diagnosing systemic amyloidosis may be challenging,
particularly in centres with no access to newer non-invasive diagnos-
tic tools such as DPD or SAP scintigraphy. Although FPFNA is a sim-
ple, safe, and inexpensive technique with a recognized role in
diagnosis of amyloidosis generally, it has important limitations, includ-
ing low sensitivity in patients with a small total body amyloid burden
and those with ATTR amyloidosis and predominant cardiac disease,
and cannot be used to exclude amyloidosis. Obtaining a biopsy from
an organ that is thought to be clinically affected by amyloid continues
to be a diagnostic requirement in a substantial proportion of patients
who are suspected of having systemic amyloidosis.
Supplementary material
Supplementary material is available at European Heart Journal online.
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